Triazole derivatives as potential xanthine oxidase inhibitors: Design, enzyme inhibition potential, and docking studies.
Arch Pharm (Weinheim)
; 357(4): e2300296, 2024 Apr.
Article
in En
| MEDLINE
| ID: mdl-38196114
ABSTRACT
Considerable ingenuity has been shown in the recent years in the discovery of novel xanthine oxidase (XO) inhibitors that fall outside the purine scaffold. The triazole nucleus has been the cornerstone for the development of many enzyme inhibitors for the clinical management of several diseases, where hyperuricemia is one of them. Here, we give a critical overview of significant research on triazole-based XO inhibitors, with respect to their design, synthesis, inhibition potential, toxicity, and docking studies, done till now. Based on these literature findings, we can expect a burst of modifications on triazole-based scaffolds in the near future by targeting XO, which will treat hyperuricemics, that is, painful conditions like gout that at present are hard to deal with.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Xanthine Oxidase
/
Hyperuricemia
Limits:
Humans
Language:
En
Journal:
Arch Pharm (Weinheim)
/
Arch. pharm
/
Archiv der pharmazie
Year:
2024
Document type:
Article
Affiliation country:
India
Country of publication:
Germany